EUCAIM Grows: 19 New Partners Join the Consortium

We are proud to announce that EUCAIM continues to grow! Following the successful launch of the 2024 Open Call, 19 new partners have officially joined the EUCAIM Consortium, effective date of January 1, 2025, expanding our collaborative network and further strengthening our mission to revolutionise cancer diagnosis and treatment through AI-powered imaging.


This significant expansion marks a major milestone for the project, reinforcing the scientific, clinical, and technological foundation of EUCAIM. The new partners bring diverse expertise across oncology, medical imaging, AI research, clinical data management, and patient advocacy, reflecting our commitment to foster cross-disciplinary collaboration across Europe.



The newly joined organisations

Data holders:

 

    • Oslo University Hospital (OUS) – Norway

    • University of Latvia (LU) – Latvia

    • HM Hospitales Research Foundation – Spain

    • CETIR Centre Mèdic – Spain

    • Pohjois-Savon Hyvinvointialue (PSHVA) – Finland

    • FISEVI – Foundation for the Management of Health Research in Seville – Spain

    • University of Athens (UoA) – Greece

    • IACS – Institute for Health Sciences of Aragon – Spain

Data users:

 

    • Better Medicine OU (BM) – Estonia


    • Sycai Technologies – Spain

    • Gdańsk University of Technology (Gdańsk Tech) – Poland

    • University Hospital Heidelberg (UKHD) – Germany

    • European Institute of Oncology (IEO) – Italy

    • VICOMTECH – Visual Interaction and Communications Technologies Centre – Spain

    • University of Bari Aldo Moro (UNIBA) – Italy

Combined data holder and data users:

 

    • Amsterdam University Medical Center (AUMC) – Netherlands

    • ISABIAL – Alicante Institute for Health and Biomedical Research – Spain

    • LPCC-NRC – Liga Portuguesa Contra o Cancro – Portugal

    • National Hellenic Research Foundation (NHRF) – Greece

We warmly welcome all new partners to the EUCAIM Consortium and look forward to the collaborative breakthroughs ahead.

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Find out more

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

WATCH THE RECORDING

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

Sign up for more information

SAVE THE DATE
March 14, 10:00-11:30 aM CET

DISCOVER THE CANCER IMAGE EUROPE PLATFORM

TECHNICAL DEMONSTRATION WEBINAR

Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.

Participate